FiercePharma2h
Alnylam touts Amvuttra's potential move into ATTR-CM as a 'market-growth story'
As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra ...
STAT6d
FDA clinical trial inclusivity guidelines will be back
Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...
Senators call on FDA to act against misleading weight-loss drug commercials
Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out the advertisement of prescriptions for injectable weight-loss drugs without ...
USA Today12d
FDA approves new pain medicine as opioid alternative. What to know about Journavx
The approval was announced in an FDA press release, and it will be sold under the brand name Journavx by Vertex Pharmaceuticals. This painkiller's approval reflects the FDA’s commitment to ...
medtechdive2d
Former FDA head Gottlieb calls for less regulation of certain AI tools
Gottlieb, who led the agency during the first Trump presidency, supports a reversion to an earlier interpretation of the 21st ...
USA Today13d
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The drug, suzetrigine, received the FDA's official stamp of approval Thursday to be sold as a 50-milligram prescription pill taken every 12 hours, according to a press release. The medication will ...
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...